natgillin/translations-raw huggingface dataset:
865 patients with leukaemia treated with dasatinib in Phase II clinical studies, the mean changes from baseline in QTc interval using Fridericia's method (QTcF) were 4 - 6 msec; the upper 95% confidence intervals for all mean changes from baseline were &lt; 7 msec (see section 4.8).
U 865 bolesnika s leukemijom koji su bili liječeni dasatinibom u kliničkim ispitivanjima faze II, prosječne promjene od početnih vrijednosti QTc intervala prema Fridericija metodi (QTcF) iznosile su 4-6 msek; gornje granice 95% intervala pouzdanosti za sve prosječne promjene u odnosu na početne vrijednosti bile su &lt; 7 msek (vidjeti dio 4.8).
890 &amp; 5 mg
890 i 5 mg
891 &amp; 20 mg
891 i 20 mg
892 &amp; 100 mg
892 i 100 mg
893 &amp; 250 mg
893 i 250 mg
9 to &lt; 16
9 do &lt; 16
9.00 (3.97, 20.41)
9,00 (3,97; 20,41) p &lt; 0,0001
9.00 (3.97, 20.41) p &lt; 0.0001
9,00 (3,97; 20,41) p &lt; 0,0001
90% of patients had final extent IPA &gt; 70% by 2 hours post dose.
90% bolesnika imalo je konačnu razinu IPA &gt; 70% do 2 sata nakon uzimanja doze.
929 &amp; 140 mg
929 i 140 mg
930 &amp; 180 mg
930 i 180 mg
95 (35.4 %) p &lt; 0.028. No signs of any increase adverse effects were noted in this study.
U tom ispitivanju nije zabilježeno povećanje nuspojava.
95% CI (0.30, 0.60) p-value &lt; 0.0001
95% CI (0,30; 0,60) p-vrijednost &lt; 0,0001
95% CI for hazard ratio (0.4316 to 0.6430) p-valuea &lt; 0.0001
95% CI za omjer rizika (0,4316 do 0,6430) p-vrijednosta &lt; 0,0001
&lt; 0.0001 (1-sided and 2-sided)
&lt; 0,0001 (1-strano and 2-strano)
&lt; 0.001
p- vrijednost
&lt; 0.32 mmol/L (1.0 mg/dL) then Stribild should be discontinued.
&lt; 0,32 mmol/l (1,0 mg/dl), primjenu Stribilda se mora prekinuti.
&lt; 0.5 x 109/l), 12 % vs 5 %, and thrombocytopenia ( &lt; 20 x 109/l ), 9 % vs 3 %, in women vs men in the first cycle of therapy.
&lt; 0,5 x 109/l) i trombocitopenije ( &lt; 20 x 109/l) stupnja 4 bila je viša u žena nego u muškaraca: 12% naspram 5% kod neutropenije i 9% naspram 3% kod trombocitopenije.
&lt; 0.5 x 109/L, eltrombopag may be reinitiated at the previous effective dose.
&lt; 9 g/dL ili ABN na &lt; 0,5 x 109/L, liječenje eltrombopagom može biti ponovo započeto prethodnom učinkovitom dozom.
&lt; 0.5  109/L
&lt; 0,5  109/L
&lt; 0.65 mmol/L [ &lt; 25 mg/dL]) have not yet been established.
&lt; 0,65 mmol/L [ &lt; 25 mg/dL]) još nije ustanovljen.
&lt; 1%, 0%, and 2% for patients receiving ledipasvir/sofosbuvir + ribavirin combination therapy for 8, 12 and 24 weeks, respectively.
&lt; 1 %, 0 %, odnosno 2 % kod pacijenata koji su primali kombiniranu terapiju ledipasvirom/sofosbuvirom + ribavirin tijekom 8, 12 odnosno 24 tjedna.
&lt; 1,500 but
&lt; 1500 ali
&lt; 1.0 x 109/L and/or platelets
i/ili trombociti &lt; 50 x 109/l
&lt; 1.0 x 109/L and/or platelets
≥1,5 x 109/l i trombociti ≥75 x 109/l.
&lt; 1.0 x 109/L and/or platelets
≥1,5 x 109/l i tromociti ≥75 x 109/l.
&lt; 1.0 x 109/L and/or platelets
≥75 x 109/l
&lt; 1.0 x 109/l and/or platelets &lt; 50 x 109/l, repeat step 1 and resume Glivec at reduced dose of 300 mg.
1,5 x 109/l i trombociti 75 x 109/l. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 300 mg.
&lt; 1.0 x 109/l and/or platelets &lt; 50 x 109/l, repeat step 1 and resume Glivec at reduced dose of 400 mg.
1,5 x 109/l i trombociti 75 x 109/l. korak i nastaviti primjenu Gliveca u smanjenoj dozi od 400 mg.
&lt; 1/1,000)
Razdražljivost
&lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
&lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000), very rare ( &lt; 1/10,000), and not known (cannot be estimated from available data).
&lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the data available).
često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000); very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
&lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from available data).
&lt; 1/1000); vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000); very rare ( &lt; 1/10,000).
&lt; 1/1000); vrlo rijetko ( &lt; 1/10000).
&lt; 1/1,000); very rare ( &lt; 1/10,000).
&lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
&lt; 1/1,000); very rare ( &lt; 1/10,000); and not known (cannot be estimated from available data).
&lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); i nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/10), uncommon ( 1/1000 to &lt; 1/100) and not known (cannot be estimated from the available data).
Nuspojave su popisane po organskim sustavima i kategorijama učestalosti (vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i ≤ 1/100) i nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/10); Uncommon (≥ 1/1,000 to &lt; 1/100); Rare (≥1/10,000 to &lt; 1/1,000); Very rare ( &lt; 1/10,000).
&lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
&lt; 1/100
≥1/10 000 i &lt; 1/1000
&lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
&lt; 1/100), rijetko (≥ 1/10 000 do &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/100), rare (≥ 1/10,000 to &lt; 1/1,000), very rare ( &lt; 1/10,000), not known (frequency cannot be estimated from the available data).
&lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (učestalost se ne može procijeniti iz dostupnih podataka).
&lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000) and very rare ( &lt; 1/10,000).
&lt; 1/10), manje često (≥1/1000 i &lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
&lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); and very rare ( &lt; 1/10,000).
&lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
&lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
&lt; 1/100); rijetko (≥1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
&lt; 1/1000), very rare ( &lt; 1/10,000).
&lt; 1/100), rijetke ( &gt; 1/10 000 do &lt; 1/1000), vrlo rijetke ( &lt; 1/10 000).
&lt; 10 g/dl, and
&lt; 10 g/dl i
&lt; 10 mg/litre) was observed in 97% of patients and appeared within 7 days of initiation of treatment.
&lt; 10 mg/litra) zabilježen je kod 97% bolesnika i pojavio se u roku od 7 dana od početka liječenja.
&lt; 10 x 109/L) were observed in 3.6% and &lt; 1% of patients, respectively.
&lt; 0,5 x 109/l) i trombocitopenija (broj trombocita &lt; 10 x 109/l) zapažene su u 3,6% odnosno &lt; 1% bolesnika.
&lt; 10% absolute decrease from baseline
Apsolutno smanjenje za &lt; 10% u odnosu na početnu vrijednost
&lt; 10% points from baseline
&lt; 10 postotnih bodova od početne vrijednosti
&lt; 100,000 copies/ml
100.000 kopija/ml
&lt; 12 g/dl
&lt; 12 g/dl
&lt; 12 g/dl after 4 weeks of dose reduction
&lt; 12 g/dl nakon 4 tjedna liječenja sniženom dozom
&lt; 12 g/dl after four weeks of dose reduction
&lt; 12 g/dl nakon 4 tjedna liječenja smanjenom dozom
&lt; 12 g/dL despite 4 weeks at reduced dose
&lt; 12 g/dl unatoč 4 tjedna liječenja sniženom dozom
&lt; 12 g/dL despite 4 weeks at reduced dose
&lt; 12 g/dl unatoč 4 tjedna na sniženoj dozi
&lt; 12 g/dL despite 4 weeks at reduced dose
&lt; 12 g/dl unatoč 4-tjednom liječenju smanjenom dozom
&lt; 12 years
&lt; 12 godina
&lt; 170 g/L (10.6 mmol/L)
 170 g/L (10,6 mmol/L)
&lt; 18 years
&lt; 18 godina
&lt; 18 years) with CF and documented initial/new onset P. aeruginosa infection/colonisation received Cayston 3 times a day for a single course of 28 days.
&lt; 6 godina; 56 bolesnika u dobi od 6 do &lt; 18 godina) s CF i dokumentiranom početnom/novonastalom infekcijom/kolonizacijom P. aeruginosa primalo je Cayston 3 puta na dan tijekom jedne kure od
&lt; 2 mg/dl n (%)b
&lt; 0,2 mg/dl n (%)b
&lt; 2 months
&lt; 2 mjeseca
&lt; 2 months N=10 (%)
&lt; 2 mjeseca N = 10 (%)
&lt; 2 years
&lt; 2 godine
&lt; 2 years old
u dobi &lt; 2 godine
&lt; 2 years, 2-8 years, ≥ 9 years.
&lt; 2 godine, 2-8 godina,  9 godina.
&lt; 2%.
&lt; 2% bolesnika.
&lt; 2,000/mm3
&lt; 2.000/mm3
&lt; 2,000/mm3 (1st time)
&lt; .,000/mm3
&lt; 2,000/mm3 (1st time)
&lt; 2.000/mm3
&lt; 2,000/mm3 (4th time)
&lt; .,000/mm3 (4. put)
&lt; 2,000/mm3 (4th time)
&lt; 2.000/mm3 (4. put)
&lt; 20 copies/mL
&lt; 20 kopija/ml
&lt; 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [ &gt; 96 % CV (coefficient of variance)] compared to other renal groups [ &lt; 40 % CV].
&lt; 20 ml/min/1,73 m2), AUC posakonazola jako je varirao [ &gt; 96% CV (koeficijent varijabilnosti)] u usporedbi s drugim kategorijama bubrežne funkcije [ &lt; 40% CV].
&lt; 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [ &gt; 96 % CV (coefficient of variance)] compared to other renal groups [ &lt; 40 % CV].
CIcr &lt; 20 ml/min/1,73 m2), AUC posakonazola jako je varirao [ &gt; 96% CV (koeficijent varijabilnosti)] u usporedbi s drugim kategorijama bubrežne funkcije [ &lt; 40% CV].
&lt; 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [ &gt; 96 % CV (coefficient of variance)] compared to other renal groups [ &lt; 40 % CV].
Clcr &lt; 20 ml/min/1,73 m2), AUC posakonazola jako je varirao [ &gt; 96% CV (koeficijent varijabilnosti)] u usporedbi s drugim kategorijama bubrežne funkcije [ &lt; 40% CV].
&lt; 200 cells/mm3
&lt; 200 stanica/mm3
&lt; 25 x 109/l (adults)
&lt; 25 x 109/l (odrasli)
&lt; 250 cells/mm3 (or febrile neutropenia) discontinue treatment.
&lt; 250 stanica/mm3 (ili febrilna neutropenija): obustaviti liječenje
&lt; 250 cells/mm3 (or febrile neutropenia) discontinue treatment.
&lt; 250 stanica/mm3 (ili febrilna neutropenija): obustaviti liječenje.
&lt; 2g/24 hrs.
&lt; 2 g/24 h.
&lt; 3 log10 copies/ml
&lt; 3 log10 kopija/ml
&lt; 3 years
&lt; 3 godine
&lt; 30 (not requiring dialysis)
&lt; 30 (kojima ne treba dijaliza)
&lt; 30 g/L. Azacitidine is contraindicated in patients with advanced malignant hepatic tumours (see section 4.3).
&lt; 30 g/L. Azacitidin je kontraindiciran u bolesnika s uznapredovalim malignim tumorima jetre (vidjeti dio 4.3).
&lt; 30 ml/min
&lt; 30 ml/min
&lt; 30 ml/min) (see section 4.3).
30 ml/min) (vidjeti dio 4.3).
&lt; 30 mL/min) in studies of tenofovir alafenamide.
&lt; 30 ml/min) u ispitivanjima tenofoviralafenamida.
&lt; 30 mL/min), according to the following tables, since enoxaparin sodium exposure is significantly increased in this patient population:
&lt; 30 ml/min), prema sljedećim tablicama, budući da je izloženost enoksaparinnatriju značajno povišena u toj populaciji bolesnika:
&lt; 30 ml/min/1.73 m2) is not recommended (see sections 4.4 and 5.2).
&lt; 30 ml/min/1,73 m2) se ne preporučuje (vidjeti dijelove 4.4 i 5.2).
&lt; 30 ml/min/1.73 m2) or end stage renal disease, therefore Trulicity is not recommended in this population (see section 5.2).
&lt; 30 ml/min/1,73 m2) ili bolesnika u terminalnoj fazi bubrežne bolesti vrlo je ograničeno pa se primjena lijeka Trulicity u toj populaciji ne preporučuje (vidjeti dio 5.2).
&lt; 300 copies/ml
&lt; 300 kopija/ml
&lt; 30ml/min/1.73 m2) and/or acute kidney injury, in
&lt; 30ml/min/1,73m²) i/ili akutnom ozljedom bubrega, kod
&lt; 30ml/min/1.73 m²) and/or acute kidney injury, in
&lt; 30ml/min/1,73m²) i/ili akutnom ozljedom bubrega, kod
&lt; 4 mutations from score
&lt; 4 mutacije od ocjene
&lt; 4 seizures during 3 month
&lt; 4 napadaja tijekom početnog razdoblja od 3 mjeseca
&lt; 4 seizures during 3 month baseline period
&lt; 4 napadaja tijekom početnog razdoblja od 3 mjeseca
&lt; 4 years
&lt; 4 godine
&lt; 40% (or ≥ 10% absolute decrease from baseline)
&lt; 40% (ili apsolutno smanjenje za ≥ 10% u odnosu na početnu vrijednost)
&lt; 40% is
je LVEF &lt; 40%,
&lt; 400 copies/ml
&lt; 400 kopija /ml
&lt; 400 copies/ml
&lt; 400 kopija/ml
&lt; 400 copies/ml (95 % CI)
400 mg dvaput
&lt; 400 copies/ml ( &lt; 69 IU/ml)
&lt; 400 kopija/ml ( &lt; 69 IU/ml)
&lt; 400 copies/mL (TLOVR)
&lt; 400 kopija/mL (TLOVR)
&lt; 400 copies/ml &lt; 50 copies/ml (95 % C.I.b) (95 % C.I.b)
&lt; 400 kopija/ml &lt; 50 kopija/ml (95% C.I.b) (95% C.I.b)
&lt; 400 copies/ml &lt; 50 copies/ml (95% C.I.b) (95% C.I.b)
(95% C.I.b) (95% C.I.b)
&lt; 400 copies/ml n (%)
&lt; 400 kopija/ml n (%)
&lt; 400 HIV-1 RNA copies/ml was 63.4%.
&lt; 400 HIV-1 RNK kopija/ml bio je 63,4%.
&lt; 400 HIV-1 RNA copies/mla n (%)
&lt; 400 HIV-1 RNK kopija/mla n (%)
&lt; 5 years
&lt; 5 godina
&lt; 50 copies/ml
&lt; 50 kopija /ml
&lt; 50 copies/mL
&lt; 50 kopija/ml
&lt; 50 copies/mL (TLOVR)
&lt; 50 kopija/mL (TLOVR)
&lt; 50 copies/mL (TLOVRa))b
&lt; 50 kopija/ml (TLOVRa))b
&lt; 50 copies/mL at week 48 in the elvitegravir and raltegravir treatment arms, respectively.
&lt; 50 kopija/ml u 48. tjednu u skupini na elvitegraviru, odnosno u skupini na raltegraviru.
&lt; 50 copies/mL by prior treatment regimen
&lt; 50 kopija/ml prema prethodnom reţimu lijeĉenja
&lt; 50 copies/mL by prior treatment regimen
HIV-1 RNK &lt; 50 kopija/ml na prvotnom režimu liječenja
&lt; 50 copies/mL by prior treatment regimend
&lt; 50 kopija/ml na prvotnom režimu liječenjad
&lt; 50 copies/mL by subgroup
HIV-1 RNK &lt; 50 kopija/ml po podskupinama
&lt; 50 copies/mL when compared to patients who stayed on a ritonavir-PI in combination with two NRTIs (94% (297/317) vs 90% 143/159), treatment difference [95% CI]: +3.8% [-1.6% to 9.1%]).
&lt; 50 kopija/ml u usporedbi s bolesnicima koji su ostali na ritonaviru-PI u kombinaciji s dva NRTI-a (94% (297/317) nasuprot 90% 143/159), razlika u liječenju [95% CI]: +3,8% [-1,6% do 9,1%]).
&lt; 50 copies/mL, 3% (8/317) were considered virologic failures (HIV RNA ≥ 50 copies/mL), and 8% (26/317) did not have data available in the Week 48 window.
≥ 50 kopija/ml), a 8% (26/317) nije imalo raspoložive podatke u okviru 48. tjedna.
&lt; 50 copies/mL, n/N (%)
&lt; 50 kopija/ml, n/N (%)
&lt; 50 copies/mla
&lt; 50 kopija/mla
&lt; 50 copies/mlc
&lt; 50 kopija/ml
&lt; 50 copies/mLd
&lt; 50 kopija/mld
&lt; 50 copies/mLe
&lt; 50 kopija/ mle
&lt; 50 copies/mLe
&lt; 50 kopija/mle
&lt; 50 copies/mLf
&lt; 50 kopija/mlf
&lt; 50 HIV-1 RNA
&lt; 50 HIV-1 RNK
&lt; 50 ml/min then renal function should be re-evaluated within one week.
&lt; 50 ml/min, da onda bubrežnu funkciju treba ponovno procijeniti u roku od jednog tjedna.
&lt; 50 mL/min/1.73 m2), and 7,339 patients treated with placebo in the intention-to-treat population.
&lt; 50 ml/min/1,73 m2) i 7339 bolesnika koji su primali placebo u populaciji bolesnika predviđenoj za liječenje.
&lt; 50 mL/min/1.73 m2), and 7,339 patients treated with placebo in the intention-to-treat population.
&lt; 50 ml/min/1,73 m2) i 7339 bolesnika koji su primali placebo u populaciji predviđenoj za liječenje.
&lt; 50 x 109/l (adults)
&lt; 50 x 109/l (odrasli)
&lt; 50 x 109/l (children and adolescents)
&lt; 50 x 109/l (djeca i adolescenti)
&lt; 50 x 109/L, repeat step 1 and resume imatinib at reduced dose of 260 mg/m2.
&lt; 50 x 109/l, treba ponoviti 1. korak i nastaviti primjenu imatiniba u smanjenoj dozi od 260 mg/m2
&lt; 50 years
&lt; 50 godina
&lt; 50 × 109/l, Grade 4 &lt; 25 × 109/l); anaemia (haemoglobin Grade 3 ≥ 65 – &lt; 80 g/l, Grade 4 &lt; 65 g/l).
≥25–50 × 109/l, stupanj 4: &lt; 25 × 109/l); anemija (hemoglobin: stupanj 3 ≥65– &lt; 80 g/l, stupanj 4: &lt; 65 g/l).
&lt; 50,000/µl following at least 2 weeks of therapy
&lt; 50 000/µl nakon barem 2 tjedna liječenja
&lt; 500 copies/ml
&lt; 500 kopija/ml &lt; 50 kopija /ml
&lt; 500 copies/ml &lt; 50 copies/ml
&lt; 500 kopija/ml &lt; 50 kopija/ml
&lt; 500/mm3
&lt; 500/mm3
&lt; 55 years
&lt; 55 godina
&lt; 6 years
&lt; 6 god.
&lt; 6 years
&lt; 6 godina
&lt; 60 mL/min/1.73 m2, canagliflozin provided clinically meaningful reduction in HbA1c compared to placebo, with -0.47% for canagliflozin 100 mg and -0.52% for canagliflozin 300 mg.
&lt; 60 mL/min/1,73 m2, kanagliflozin je doveo do klinički značajnog smanjenja HbA1c u usporedbi s placebom, s -0,47% za kanagliflozin od 100 mg i -0,52% za kanagliflozin od 300 mg.
&lt; 60 mL/min; see section 4.4)
&lt; 60 ml/min; vidjeti dio 4.4)
&lt; 65 years
&lt; 65 godina
&lt; 65 years compared to subjects between 65 and 75 years (see sections 4.2 and 4.4).
&lt; 65 godina u usporedbi s bolesnicima u dobi između 65 i 75 godina (vidjeti dijelove 4.2 i 4.4).
&lt; 7.0 % or ≤ 6.5 % at 26 weeks and &lt; 7.0 % at 52 weeks than with insulin glargine.
&lt; 7,0% ili ≤ 6,5% u 26. tjednu i &lt; 7,0% u 52. tjednu uz Trulicity nego uz inzulin glargin.
&lt; 70 x 109/l (children and adolescents)
&lt; 70 x 109/l (djeca i adolescenti)
&lt; 75 x 109/l it is recommended to delay treatment until ANC recovers to ≥ 1.0 x 109/l and platelet count to ≥ 75 x 109/l.
≥ 1,0 x 109/l, a broj trombocita do ≥ 75 x 109/l.
&lt; 75 years of age and 46 patients 75 years of age to ≤ 80 years of age) with inadequate glycaemic control on current diabetes treatment (glucose-lowering medicinal products and/or diet and exercise) participated in a double-blind, placebo-controlled study over 26 weeks.
&lt; 75 godina i 46 bolesnika starosti 75 godina do ≤ 80 godina) s neprikladnom regulacijom glikemije s dosadašnjom terapijom dijabetesa (lijekovi koji snižavaju glukozu i/ili dijeta i tjelovježba) sudjelovalo je u dvostruko slijepom, placebom-kontroliranom ispitivanju kroz 26 tjedana.
&lt; 75 years of age and 46 patients 75 years of age to ≤ 80 years of age) with inadequate glycaemic control on current diabetes treatment (glucose-lowering medicinal products and/or diet and exercise) participated in a double-blind, placebo-controlled study over 26 weeks.
&lt; 75 godina i 46 bolesnika starosti 75 godina do ≤ 80 godina) s neprikladnom regulacijom glikemije s trenutnim liječenjem dijabetesa (lijekovi koji snižavaju glukozu i/ili dijeta i vježba) sudjelovalo je u dvostruko slijepom, placebo-kontroliranom ispitivanju kroz 26 tjedana.
&lt; 750 cells/μL on a Bortezomib Hospira dosing day (other than Day 1 of each cycle)
apsolutni broj neutrofila &lt; 750 stanica/μl na dan primjene doze lijeka Bortezomiba Hospira (osim 1. dana svakog ciklusa)
&lt; 8.4 mg/dl (2.1 mmol/l) and &gt; 7.5 mg/dl (1.9 mmol/l) or persistent symptoms of hypocalcaemia despite attempts to increase serum calcium
&lt; 8,4 mg/dl (2,1 mmol/l) I &gt; 7,5 mg/dl (1,9 mmol/l), ili uporni simptomi hipokalcemije unatoč pokušajima da se povisi serumski kalcij
&lt; 8.4 mg/dl (2.1 mmol/l) and &gt; 7.5 mg/dl (1.9 mmol/l), or in the presence of clinical symptoms of hypocalcaemia
&lt; 8,4 mg/dl (2,1 mmol/l) I &gt; 7,5 mg/dl (1,9 mmol/l), ili u prisutnosti kliničkih simptoma
&lt; 8.4 mg/dl (2.1 mmol/l) and &gt; 7.5 mg/dl (1.9 mmol/l), or in the presence of clinical symptoms of hypocalcaemia
&lt; 8,4 mg/dl (2,1 mmol/l) i &gt; 7,5 mg/dl (1,9 mmol/l), ili u prisutnosti kliničkih simptoma hipokalcemije
&lt; 8.5 g/dl
&lt; 8,5 g/dl
&lt; 80 mL/min/1.73 m2), moderate (eGFR ≥ 30 and &lt; 50 mL/min/1.73 m2), severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2) and patients with ESRD requiring haemodialysis following a single 400 mg dose of sofosbuvir.
&lt; 80 ml/min/1,73m2), umjerenim (eGFR ≥ 30 i &lt; 50 ml/min/1,73m2), teškim oštećenjem bubrega (eGFR &lt; 30 ml/min/1,73 m2) i pacijenata sa završnim stadijem bolesti bubrega koji su trebali hemodijalizu, nakon jedne doze od 400 mg sofosbuvira.
&lt; 80 mL/min/1.73 m2), moderate (eGFR ≥ 30 and &lt; 50 mL/min/1.73 m2), severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2) and patients with ESRD requiring haemodialysis following a single 400 mg dose of sofosbuvir.
&lt; 80 ml/min/1,73m2), umjerenim (eGFR ≥ 30 i &lt; 50 ml/min/1,73m2), teškim oštećenjem bubrega (eGFR &lt; 30 ml/min/1,73 m2) i pacijenata sa završnim stadijem bolesti bubrega koji su zahtijevali hemodijalizu, nakon jedne doze od 400 mg sofosbuvira.
&lt; 90 mL/min unless, after review of the available treatment options, it is considered that Stribild is the preferred treatment for the individual patient.
&lt; 90 ml/min, osim ako se nakon pregleda dostupnih mogućnosti liječenja ne smatra da je Stribild preferirano liječenje za pojedinog pacijenta.
&lt; 90 mL/min, no dose adjustment is needed.
&lt; 90 mL/min, nije potrebna prilagodba doze.
&lt; Grade 2 Recurrence at 15 mg:
Ponovna pojava uz 15 mg:
&lt; Grade 2 Recurrence at 30 mg:
Ponovna pojava uz 30 mg:
&lt; PC: {number} SN: {number} NN: {number} &gt;
&lt; PC: {broj} [oznaka lijeka] SN: {broj} [serijalizacijski broj]
&lt; see side 1
&lt; pogledajte 1. stranicu
&lt; see side 1
&lt; pogledajte stranicu 1
&lt; 0.001
placeba)
&lt; 0.001
udar/UCR)
&lt; 0.75 or APRI &gt; 1 to ≤2).
&lt; 0,75 ili APRI &gt; 1 do ≤2).
&lt; 0.8x109/L or &lt; 0.5x109/L. During treatment with Tecfidera in the MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% from baseline at one year and then plateaued (see section 4.8).
Tijekom liječenja Tecfiderom u placebom kontroliranim ispitivanjima MS-a, srednja vrijednost broja limfocita smanjila se za otprilike 30% od početne vrijednosti tijekom prve godine nakon čega je uslijedio plato (vidjeti dio 4.8).
&lt; 1,000 cells/mm3) have not been investigated.
&lt; 1000 stanica/mm3) nisu ispitane.
&lt; 1,000 cells/mm3) or severely immunocompromised patients.
&lt; 1000 stanica/mm3) niti teško imunokompromitirane bolesnike.
&lt; 1.0x109/1 and/or platelets &lt; 50x109/1, repeat step1 and resume Imatinib Accordat reduced dose of 400 mg.
1,5 x 109/l i trombociti 75 x 109/l. nastaviti primjenu Imatinib Accorda u smanjenoj dozi od 400 mg.
&lt; 1.0x109/1 and/or platelets &lt; 50x109/1, repeat step1 and resume Imatinib Accordat reduced dose of 400 mg.
1,5 x 109/l i trombociti75 x 109/l. nastaviti primjenu Imatinib Accorda u smanjenoj dozi od400 mg.
&lt; 1.25 X upper normal limit
&lt; 1,25 puta gornja normalna granica
&lt; 1.5 x upper limit of normal value (ULN)
&lt; 1,5 x gornja granica normale (GGN)
&lt; 1/1,000) and very rare ( &lt; 1/10,000).
&lt; 1/100), rijetko (≥1/10 000 i &lt; 1/1000) i vrlo rijetko ( &lt; 1/10 000).
&lt; 1/1,000), including isolated reports; not known (cannot be estimated from the available data)
&lt; 1/1000), uključujući izolirane slučajeve; nepoznato (ne može se procijeniti iz dostupnih podataka)
&lt; 1/1,000), Very rare ( &lt; 1/10,000), Not known (cannot be estimated from the available data)
&lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka)
&lt; 1/1,000), very rare ( &lt; 1/10,000) and not known (cannot be estimated from the available data).
&lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000), very rare ( &lt; 1/10,000), and not known (cannot be estimated from the available data).
&lt; 1/1000), vrlo rijetko ( &lt; 1/10 000) i nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000); and very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
&lt; 1/1000); i vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
&lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nije poznato (ne može se procijeniti iz dostupnih podataka).
&lt; 1/1,000); very rare ( &lt; 1/10,000), not known (cannot be estimated from the available data).
&lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).